SI2107069T1 - Novi inzulinski derivati - Google Patents
Novi inzulinski derivatiInfo
- Publication number
- SI2107069T1 SI2107069T1 SI200432008T SI200432008T SI2107069T1 SI 2107069 T1 SI2107069 T1 SI 2107069T1 SI 200432008 T SI200432008 T SI 200432008T SI 200432008 T SI200432008 T SI 200432008T SI 2107069 T1 SI2107069 T1 SI 2107069T1
- Authority
- SI
- Slovenia
- Prior art keywords
- insulin derivatives
- novel insulin
- novel
- derivatives
- insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301129 | 2003-08-05 | ||
US49545103P | 2003-08-14 | 2003-08-14 | |
EP09165072A EP2107069B1 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2107069T1 true SI2107069T1 (sl) | 2013-04-30 |
Family
ID=36947523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200432008T SI2107069T1 (sl) | 2003-08-05 | 2004-07-22 | Novi inzulinski derivati |
Country Status (10)
Country | Link |
---|---|
EP (3) | EP2287184A3 (sl) |
KR (1) | KR101186851B1 (sl) |
CN (2) | CN1829738B (sl) |
DK (2) | DK2275439T3 (sl) |
ES (2) | ES2402592T3 (sl) |
PL (1) | PL2275439T3 (sl) |
PT (2) | PT2275439E (sl) |
RU (1) | RU2352581C2 (sl) |
SI (1) | SI2107069T1 (sl) |
ZA (1) | ZA200600846B (sl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
DE602004026113D1 (de) | 2003-12-18 | 2010-04-29 | Novo Nordisk As | Glp-1-verbindungen |
EP1969004B1 (en) | 2005-12-28 | 2011-08-10 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー/エス | インスリン誘導体を含有する薬学的製剤 |
CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
RU2540922C2 (ru) | 2008-10-30 | 2015-02-10 | Ново Нордиск А/С | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
US20130143803A1 (en) * | 2010-05-10 | 2013-06-06 | Novo Nordisk A/S | Process for the Preparation of Insulin-Zinc Complexes |
RS59423B1 (sr) * | 2010-10-27 | 2019-11-29 | Novo Nordisk As | Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja |
BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
CN103443122B (zh) | 2011-12-15 | 2016-05-11 | 上海恒瑞医药有限公司 | 人胰岛素类似物及其酰化衍生物 |
AU2013255880B2 (en) | 2012-05-01 | 2017-07-20 | Novo Nordisk A/S | Pharmaceutical composition |
WO2014147141A1 (en) * | 2013-03-20 | 2014-09-25 | Novo Nordisk A/S | Insulin dosing regimen |
EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
CN103467594A (zh) * | 2013-09-12 | 2013-12-25 | 深圳先进技术研究院 | 胰岛素修饰物及其制备方法和应用 |
CN105001140B (zh) * | 2015-06-29 | 2018-01-05 | 珠海联邦制药股份有限公司 | 一种制备脂肪二酸衍生物的方法及其应用 |
CN106496322A (zh) * | 2015-09-07 | 2017-03-15 | 江苏恒瑞医药股份有限公司 | 人胰岛素或其类似物的酰化衍生物的制备方法 |
EP3495384A4 (en) | 2016-08-02 | 2020-02-26 | Jiangsu Hengrui Medicine Co., Ltd. | ACYLATED DERIVATIVE OF HUMAN INSULIN OR ANALOGUE OF IT |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
CN111518009B (zh) * | 2019-02-01 | 2023-06-23 | 鲁南制药集团股份有限公司 | 一种脂肪酸衍生物及其合成方法 |
CN113045473A (zh) * | 2020-03-18 | 2021-06-29 | 广东东阳光药业有限公司 | 制备长脂肪链二酸衍生物的方法及其应用 |
CN114075275A (zh) * | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
CN116903512A (zh) * | 2023-06-05 | 2023-10-20 | 浙江湃肽生物股份有限公司深圳分公司 | 一种德谷胰岛素中间体及其德谷胰岛素的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
DK45590D0 (sl) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
RO112873B1 (ro) | 1993-09-17 | 1998-01-30 | Novo Nordisk As | Derivati de insulina |
US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
PT938502E (pt) * | 1996-07-11 | 2005-02-28 | Novo Nordisk As | Metodo selectivo por acilacao |
US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
CA2308705A1 (en) * | 1997-10-24 | 1999-05-06 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
US20020155994A1 (en) | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
-
2004
- 2004-07-22 ES ES09165072T patent/ES2402592T3/es not_active Expired - Lifetime
- 2004-07-22 PT PT101744944T patent/PT2275439E/pt unknown
- 2004-07-22 CN CN2004800217338A patent/CN1829738B/zh not_active Expired - Lifetime
- 2004-07-22 CN CN201010514501.3A patent/CN101955527B/zh not_active Expired - Lifetime
- 2004-07-22 PT PT91650721T patent/PT2107069E/pt unknown
- 2004-07-22 RU RU2006103280/04A patent/RU2352581C2/ru active Protection Beyond IP Right Term
- 2004-07-22 EP EP10174493A patent/EP2287184A3/en not_active Withdrawn
- 2004-07-22 EP EP10174491A patent/EP2264066A3/en not_active Withdrawn
- 2004-07-22 ES ES10174494.4T patent/ES2472421T3/es not_active Expired - Lifetime
- 2004-07-22 DK DK10174494.4T patent/DK2275439T3/da active
- 2004-07-22 SI SI200432008T patent/SI2107069T1/sl unknown
- 2004-07-22 EP EP10174494.4A patent/EP2275439B1/en not_active Expired - Lifetime
- 2004-07-22 DK DK09165072.1T patent/DK2107069T3/da active
- 2004-07-22 KR KR1020127002621A patent/KR101186851B1/ko active Protection Beyond IP Right Term
- 2004-07-22 PL PL10174494T patent/PL2275439T3/pl unknown
-
2006
- 2006-01-30 ZA ZA200600846A patent/ZA200600846B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK2107069T3 (da) | 2013-04-15 |
PT2107069E (pt) | 2013-04-23 |
CN1829738B (zh) | 2012-07-04 |
EP2275439B1 (en) | 2014-03-26 |
ZA200600846B (en) | 2007-04-25 |
KR20120026629A (ko) | 2012-03-19 |
EP2287184A2 (en) | 2011-02-23 |
CN101955527B (zh) | 2016-04-20 |
EP2275439A3 (en) | 2011-03-23 |
ES2472421T3 (es) | 2014-07-01 |
RU2352581C2 (ru) | 2009-04-20 |
PT2275439E (pt) | 2014-06-25 |
EP2264066A3 (en) | 2011-07-27 |
PL2275439T3 (pl) | 2014-09-30 |
KR101186851B1 (ko) | 2012-10-02 |
CN101955527A (zh) | 2011-01-26 |
CN1829738A (zh) | 2006-09-06 |
EP2287184A3 (en) | 2011-08-10 |
EP2275439A2 (en) | 2011-01-19 |
ES2402592T3 (es) | 2013-05-07 |
DK2275439T3 (da) | 2014-05-12 |
RU2006103280A (ru) | 2007-09-20 |
EP2264066A2 (en) | 2010-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1300033I1 (hu) | Új inzulin származékok | |
IL169905A0 (en) | Novel 2-pyridinecarboxamide derivatives | |
IL174154A0 (en) | Novel glp-1 derivatives | |
HK1088326A1 (en) | Piperidine-benzenesulfonamide derivatives | |
PL1694385T3 (pl) | Zestaw do infuzji | |
HK1089443A1 (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
GB0317665D0 (en) | Qinazoline derivatives | |
PL1682493T3 (pl) | Pochodne amidoacetonitrylu | |
SI2107069T1 (sl) | Novi inzulinski derivati | |
IL175189A0 (en) | N-thiazol-2-yl-benzamide derivatives | |
TWI368482B (en) | New 2-pyridinylethylbenzamide derivatives | |
EP1661594A4 (en) | SYRINGE | |
AU2003259457A8 (en) | Auto-destructible syringe | |
PL1706373T3 (pl) | Pochodne amidoacetonitrylu | |
GB0329269D0 (en) | Syringe | |
GB0312368D0 (en) | Novel ureido- and amido-pyrazolone derivatives | |
GB2401043B (en) | Drug | |
GB0319793D0 (en) | Pyridinylmorpholine derivatives | |
EP1624073A4 (en) | DRUG | |
TWI341309B (en) | Heteroarylcarbamoylbenzene derivatives | |
GB0319148D0 (en) | Azaquinazoline derivatives | |
AU2003280822A8 (en) | Beauveriolide derivatives | |
HU0300481D0 (en) | Syringe | |
GB0318854D0 (en) | Self-sterilising syringe | |
HU0300508D0 (en) | Syringe |